Compliance in an Outsource Manufacturing Model: What to Look For - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Compliance in an Outsource Manufacturing Model: What to Look For
The authors provide detailed lists of important checkpoints to consider when selecting an outsourcing provider.


Pharmaceutical Technology


Atypical and OOS results

  • Is there a standard operating procedure (SOP) for investigation of out of specification (OOS) results?
  • Does it describe notification, investigations, product impact, corrective actions, trending, regulatory reporting?
  • Are investigations performed in a timely manner?
  • Are investigations thorough and complete?
  • Are corrective actions followed up in a timely manner?
  • Is there trending of discrepancies?

Documentation control and approval

  • Is all documentation associated with the routine testing approved?
  • Does the QA unit have an authorized person or department specifically charged with the responsibility of obtaining approval by signature/date for production and testing procedures, forms, and records?
  • Is there an SOP that defines the scope and roles and responsibilities for the document control and retention system?
  • Are all production and control records specifically associated with a batch maintained at least one year after the expiration date of the batch?
  • Is there a document control procedure that would prevent the use of invalid or obsolete documents?
  • Is there an SOP that addresses 21 CFR Part 11 issues?

Change control

  • Are there SOPs covering all elements of the change control process? Do change requests include description, requirements (e.g., revalidation), impact evaluation, and effective date designation?
  • Is change control documented, evaluated, and approved?
  • Is a procedure in place to ensure that personnel are trained on the changes in a timely manner?
  • Are customers notified of critical changes?
  • Review some change requests and ensure that they are implemented according to procedure.

Training

  • Is there an SOP describing training?
  • Are personnel trained to perform their assigned tasks? By what method? Are training materials, including GMP training materials, available?
  • Indicate how on-going, periodic GMP training is accomplished, including training following an operator or analyst error.
  • Is all training documented in writing that indicates the date of the training, the type of training, and the signature of both the employee and the trainer?
  • Is there adequate staffing?

Internal quality and GMP audit program

  • Does a formal auditing function exist in the QA department?
  • Does a written SOP specify who shall conduct audits and qualifications (education, training, and experience) for those who conduct audits?
  • Does a written SOP specify the scope and frequency of audits and how such audits are to be documented?
  • Does a written SOP specify the distribution of the audit report?

Facility layout and design

  • Are there designated areas for raw materials, components, in-process materials, and packaging materials?
  • Is the facility temperature and humidity monitored?
  • Is there a designated area for sampling and dispensing of raw materials in a controlled environment to prevent contamination?
  • Are there designated processing areas with air monitored for temperature, humidity, and room differential pressures?
  • Is there sufficient space in the facility for the type of work and typical volume of production to prevent mix-ups?
  • Is there a written procedure for the prevention of infestation from rodents, birds, insects, and vermin? Is the facility free from infestation?
  • Is the facility maintained in a clean, well-maintained, and sanitary condition?
  • Does the facility have written procedures that sufficiently detail the cleaning schedule, methods, equipment and materials?
  • Are all parts of the facility maintained in a good state of repair?

Environmental control program

  • Is there a formal environmental monitoring system?
  • Is the facility not situated in a location that potentially subjects workers or product to particulate matter, fumes, or infestations?
  • Is the lighting adequate in all areas?
  • Is adequate ventilation provided?
  • Are hard smooth surfaces easily cleanable?
  • Is control of air pressure, dust, humidity and temperature adequate for the storage and testing of drug products?
  • Is there a written procedure specifying the frequency of inspection and replacement of HEPA filters?


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
How does your company apply quality-by-design (QbD) principles to manufacturing processes?
To all processes for both new and legacy products
To all process for new products only
To select process for new products only
To select processes for both new and legacy products
Do not use QbD
To all processes for both new and legacy products
18%
To all process for new products only
14%
To select process for new products only
23%
To select processes for both new and legacy products
20%
Do not use QbD
25%
View Results
UPCOMING CONFERENCES

Programs for Investigational and Pre-Launch Drugs
Philadelphia, PA
July 17-18, 2013
Request Brochure

Strategic Pipeline Planning & Portfolio Valuation
Philadelphia, PA
August 13-14, 2013
Request Brochure

MES 2013 - Forum on Manufacturing Execution Systems
Philadelphia, PA
August 14-15, 2013
Request Brochure

Mobile Innovation for the Life Sciences Industry
Philadelphia, PA
August 20-21, 2013
Request Brochure

See All Conferences >>

Eric Langer Outsourcing Outlook Eric LangerOutsourcing's Modest Role as a Cost-Containment Strategy
Patricia Van Arnum Ingredients Insider Patricia Van ArnumIntellectual Property Battles in Solid-State Chemistry
Nathan Jessop Industry Insider Nathan Jessop Campaign Against Counterfeit Drugs Continues
Lynn Torbeck Statistical Solutions Lynn D. TorbeckCompositing Samples and the Risk to Product Quality
 More
Inadequate Access to Medicines Puts EU at Risk
FDA Offers Insight on QbD for Modified-Release Products
Global Biosimilars Market to Reach $2.445 Billion in 2013
Adapting to Change
AstraZeneca and Exco InTouch Collaborate to Augment Current COPD Pathways
FindPharma Custom Search
Source: Pharmaceutical Technology,
Click here